262 research outputs found
sj-pdf-3-wso-10.1177_17474930211044870 - Supplemental material for Therapeutic hypothermia for intracerebral hemorrhage: Systematic review and meta-analysis of the experimental and clinical literature
No full textSupplemental material, sj-pdf-3-wso-10.1177_17474930211044870 for Therapeutic hypothermia for intracerebral hemorrhage: Systematic review and meta-analysis of the experimental and clinical literature by Turner S Baker, John Durbin, Zachary Troiani, Luis Ascanio-Cortez, Rebecca Barron, Anthony Costa, Fred Rincon, Frederick Colbourne, Patrick Lyden, Stephan A Mayer and Christopher P Kellner in International Journal of Stroke</p
sj-pdf-1-wso-10.1177_17474930211044870 - Supplemental material for Therapeutic hypothermia for intracerebral hemorrhage: Systematic review and meta-analysis of the experimental and clinical literature
No full textSupplemental material, sj-pdf-1-wso-10.1177_17474930211044870 for Therapeutic hypothermia for intracerebral hemorrhage: Systematic review and meta-analysis of the experimental and clinical literature by Turner S Baker, John Durbin, Zachary Troiani, Luis Ascanio-Cortez, Rebecca Barron, Anthony Costa, Fred Rincon, Frederick Colbourne, Patrick Lyden, Stephan A Mayer and Christopher P Kellner in International Journal of Stroke</p
Thrombolysis is associated with consistent functional improvement across baseline stroke severity: a comparison of outcomes in patients from the Virtual International Stroke Trials Archive (VISTA)
No full text<p><b>Background and Purpose:</b> Baseline stroke severity predicts outcomes among thrombolysed patients. The baseline National Institutes of Health Stroke Scale (NIHSS) thresholds are sometimes used to select patients for thrombolysis, clinical trial enrollment, or both. Using data lodged with Virtual International Stroke Trials Archive, we compared adjusted outcomes between thrombolysed and nonthrombolysed patients enrolled in neuroprotection trials (1998-2007) to assess the influence of various levels of baseline NIHSS.</p>
<p><b>Method:</b> We assessed the association of treatment with outcome, measured across the modified Rankin scale score distribution, in patients categorized by baseline NIHSS in increments of 4. We used an age and baseline NIHSS adjusted Cochran-Mantel-Haenszel test followed by proportional odds logistic regression analysis. We report the Cochran-Mantel-Haenszel P values and estimated odds ratios (OR) for improved modified Rankin scale score distribution with treatment for patients within each baseline NIHSS category.</p>
<p><b>Results:</b> Data were available for 5817 patients (1585 thrombolysed and 4232 nonthrombolysed). Baseline severity was greater among thrombolysed than nonthrombolysed (median baseline NIHSS, 14 vs 13; P<0.05). An association of treatment with outcome was seen independently and was of similar magnitude within each of the baseline NIHSS categories 5 to 8 (P=0.04; OR, 1.25; 95% confidence interval [CI], 1.0-1.6; N=278/934 thrombolysed/nonthrombolysed), 9 to 12 (P=0.01; OR, 1.3; 95% CI, 1.1-1.6; N=404/942), 13 to 16 (P<0.05; OR, 1.6; 95% CI, 1.3-2.1; N=342/814), 17 to 20 (P<0.05; OR, 1.7; 95% CI, 1.3-2.1; N=311/736), and 21 to 24 (P<0.05; OR, 1.6; 95% CI, 1.1-2.1; N=178/466). No association was observed within baseline NIHSS categories 1 to 4 (P=0.8; OR, 1.1; 95% CI, 0.3-4.4; N=8/161) or >= 25 (P=0.08; OR, 1.1; 95% CI, 0.7-1.9; N=64/179).</p>
<p><b>Conclusions:</b> In this nonrandomized comparison, outcomes after thrombolysis were significantly better than in untreated comparators across baseline NIHSS 5 to 24. The significant association was lost only at extremes of baseline NIHSS when sample sizes were small and confidence limits were wide.</p>
sj-pdf-2-wso-10.1177_17474930211044870 - Supplemental material for Therapeutic hypothermia for intracerebral hemorrhage: Systematic review and meta-analysis of the experimental and clinical literature
No full textSupplemental material, sj-pdf-2-wso-10.1177_17474930211044870 for Therapeutic hypothermia for intracerebral hemorrhage: Systematic review and meta-analysis of the experimental and clinical literature by Turner S Baker, John Durbin, Zachary Troiani, Luis Ascanio-Cortez, Rebecca Barron, Anthony Costa, Fred Rincon, Frederick Colbourne, Patrick Lyden, Stephan A Mayer and Christopher P Kellner in International Journal of Stroke</p
Immunotherapy
No full textA chapter covering metastasis immunotherapy in multi-author volume devoted to all aspects of cancer metastasis
Hong Kong Medical Forum '97: programme book : 26th-27th July 1997, Hong Kong Convention & Exhibition Centre.
No full textpublished_or_final_versionProgramme - 26th July 1997, Saturday 2Programme - 27th July 1997, Sunday 3Speakers 4Acknowledgment 24AbstractsBrief synopsis of presentation on Klatskin's tumors Pellegrini, Carlos A. Pellegrini, Carlos A. 5Indications for liver transplantation Maddrey, Willis C. Maddrey, Willis C. 6Auxiliary liver transplantation for fulminant hepatic failure Belghiti, Jacques Belghiti, Jacques 8Post-liver transplant medical complications Maddrey, Willis C. Maddrey, Willis C. 9Helicobacter pylori - where do we stand now? Misiewicz, J.J. Misiewicz, J.J. 10Helicobacter pylori and upper gastrointestinal surgery Chu, Kent-man Chu, Kent-man 11Guidelines for the eradication of helicobactor pylori Misiewicz, J.J. Misiewicz, J.J. 12An update on viral hepatitis Maddrey, Willis C. Maddrey, Willis C. 13Thrombolysis for acute stroke Lyden, Patrick D. Lyden, Patrick D. 14Angioplasty and stenting of extracranial cerebral arteries for prevention of strokes Ho, David S.W. Ho, David S.W. 16Acute stroke therapy in Hong Kong Cheung, Raymond T.F. Cheung, Raymond T.F. 17How to run a stroke code Lyden, Patrick D. Lyden, Patrick D. 18Diabetic nephropathy : natural history and therapeutic interventions Lewis, Edmund J. Lewis, Edmund J. 19Pathogenesis and therapeutic interventions in progressive renal diseases Breyer, Julia A. Breyer, Julia A. 20Management of severe lupus nephritis Chan, Daniel T.M. Chan, Daniel T.M. 21Immunotactoid glomerulopathy Lewis, Edmund J. Lewis, Edmund J. 22Renal transplantation : local issues Cheng, Ignatius K.P. Cheng, Ignatius K.P. 2
sj-docx-1-wso-10.1177_17474930231187268 – Supplemental material for Analysis of brain edema in RHAPSODY
No full textSupplemental material, sj-docx-1-wso-10.1177_17474930231187268 for Analysis of brain edema in RHAPSODY by Riana L Schleicher, Pongpat Vorasayan, Megan E McCabe, Matthew B Bevers, Thomas P Davis, John H Griffin, Archana Hinduja, Ashutosh P Jadhav, Jin-Moo Lee, Robert N Sawyer Jr, Berislav V Zlokovic, Kevin N Sheth, Janel K Fedler, Patrick Lyden and W Taylor Kimberly in International Journal of Stroke</p
Huntsville Times sleeve HT0004867
No full textAuthor "Daughter of the Queen of Sheba" / NPR foreign correspondent. / Jackie Lyden / WLRH on UAH [University of Alabama in Huntsville] campus / Author of book being made into major motion picture starring Meryl Streep and Gwyneth Paltrow about living with manic-depressive mom
The Future of Basic Science Research and Stroke: Hubris and Translational Stroke Research
No full textA multi-laboratory preclinical trial to assess treatment candidates for acute ischemic stroke
No full textHuman diseases may be modeled in animals to allow preclinical assessment of putative new clinical interventions. Recent, highly publicized failures of large clinical trials called into question the rigor, design, and value of preclinical assessment. We established the Stroke Preclinical Assessment Network (SPAN) to design and implement a randomized, controlled, blinded, multi-laboratory network for the rigorous assessment of candidate stroke treatments combined with intravascular thrombectomy. Futility boundaries in a Multi-Arm Multi-Stage statistical design aimed to exclude less effective interventions, and efficacy boundaries allowed early declaration of success after each of four sequential stages. Six independent research laboratories performed a standard focal cerebral ischemic insult in five animal models that included equal numbers of males and females: young mice, young rats, aging mice, mice with diet-induced obesity, and spontaneously hypertensive rats. The laboratories adhered to a common protocol and efficiently enrolled 2,615 animals with full data completion and comprehensive animal tracking. SPAN successfully implemented treatment masking, randomization, pre-randomization inclusion and exclusion criteria, and blinded assessment of outcomes. The SPAN design and infrastructure provide an effective approach that could be used in similar preclinical, multi-laboratory studies in other disease areas, and should help improve reproducibility in translational science.Tables contain the results of the corner test and the MR imaging organized by subject ID. Treatment group data is available in the feasibility file. These are contained in the following files:
dt_feasibility_stm_paper 2023-08-21dt_outcome_corner_stm_paper 2023-08-21dt_outcome_mri_stm_paper 2023-08-21report_stm_paper 2023-07-29
The first 3 files are Excel files that contain data listings in tab 1 and data definition dictionary in tab 2. The treatment group variables can be found in the first file and applied to the remaining files by matching on the animal identity variable "enro_animal_id. The variable 'txas_tx_group' contains a code that gives the treatment group to which the subject was assigned. The variable 'txas_tx_group_actual' gives a code for the treatment group actually received. The corresponding drug treatment names can be found in tab 2 and in the main paper itself. The final html file is a report used to define the various study populations, including the enrolled (pop_enro), the inelegible to be randomized, the intention to treat (pop_itt), the excluded animals, the procedural dropouts, the modified intention to treat (pop_mitt), the partial treatments, the per protocol treated animals, and the loss to followup (died) animals. Funding provided by: National Institute of Neurological Disorders and StrokeCrossref Funder Registry ID: http://dx.doi.org/10.13039/100000065Award Number: U24NS113452Funding provided by: National Institute of Neurological Disorders and StrokeCrossref Funder Registry ID: http://dx.doi.org/10.13039/100000065Award Number: U01NS113356Funding provided by: National Institute of Neurological Disorders and StrokeCrossref Funder Registry ID: http://dx.doi.org/10.13039/100000065Award Number: U01NS113443Funding provided by: National Institute of Neurological Disorders and StrokeCrossref Funder Registry ID: http://dx.doi.org/10.13039/100000065Award Number: U01NS113445Funding provided by: National Institute of Neurological Disorders and StrokeCrossref Funder Registry ID: http://dx.doi.org/10.13039/100000065Award Number: U01NS113388Funding provided by: National Institute of Neurological Disorders and StrokeCrossref Funder Registry ID: http://dx.doi.org/10.13039/100000065Award Number: U01NS113451Funding provided by: National Institute of Neurological Disorders and StrokeCrossref Funder Registry ID: http://dx.doi.org/10.13039/100000065Award Number: U01NS113444SPAN consists of six research laboratories to conduct preclinical stroke modeling and a coordinating center to mask drugs, conduct centralized randomization, assess blinded outcomes, collect data, and perform statistics. The aim of SPAN was to determine whether such rigor is feasible and practical on a large scale in a multi-laboratory controlled, randomized preclinical study of six investigator-initiated putative interventions for acute ischemic stroke, selected through a rigorous NIH-peer review. Here we report the primary results of SPAN
- …
